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Summary.-The relation between terminal deoxynucleotidyl transferase (TdT)
activity, glucocorticoid (GC) receptors and the effect of vincristine-prednisolone
(VP) therapy on fresh leukaemia cases was examined. Five of 6 TdT+ leukaemias
showed high levels of GC receptors and a favourable response to VP therapy, whereas
1 acute lymphoblastic leukaemia (ALL) and 3 of chronic myelogenous leukaemia
(CML) cases in blast crisis with no TdT activity showed low level of GC receptors and
poor response to VP therapy.
Significant correlation (r=0-821, P<0-01) was observed between TdT activity and
the number of GC receptor sites in these cases. x2 test showed significant difference
(P<0-01) between TdT+ and TdT- leukaemias in the effect of VP. A significant
difference (P<0-01) was also observed between VP-effective and ineffectiveleukaemias
in the number of GC-receptor sites by unpaired t test. Therefore GC receptors may
be responsible for the effect of VP on TdT+ leukaemias.
TERMINAL deoxynucleotidyl transferase
(TdT) is a DNA polymerase with a unique
distribution (Bollum, 1979). Since the
discovery of high TdT activity in blasts of
an ALL case (McCaffrey et al., 1973) there
have been many studies on this enzyme in
leukaemia. Thus far, in most cases ofALL
(Coleman et al., 1976; Greenwood et al.,
1977), in about one third of cases with
CML in blast crisis (Sarin et al., 1976;
Sasaki & Sakamoto, 1977) and in a few
cases with acute myelogenous leukaemia
(AML) (Stass et al., 1979), high enzyme
activities were reported. Recently, there
are some reports suggesting that vincris-
tine-prednisolone (VP) therapy is effective
for the treatment of TdT+ leukaemia
cases (Marks et al., 1978; Sasaki et al.,
1979; Pangalis & Beutler, 1979).
However, we know of no report on
the relation between TdT activity, the
level of glucocorticoid (GC) receptors of
blasts and the effect of VP therapy on
leukaemia. This study aimed to investi-
gate the mechanism of the effect of VP
therapy on TdT+ leukaemias.
MATERIALS AND METHODS
Chemicals.-[1,2 (n)-3H] dexamethasone
(24 Ci/mmol) and deoxy [8-3H] guanosine
5'-triphosphate [3H-dGTP, 7-7 Ci/mmol]
were purchased from Amersham Co., Ill.
Polydeoxyadenylic acid (Poly-dA) was from
P-L Biochemicals Inc., Milwaukee, Wisc.
Materials. - Leukaemic blasts were ob-
tained from peripheral blood and marrow of
fresh leukaemia cases, and separated with a
dextran sodium metrizoate solution or with
Ficoll-Hypaque solution, as described pre-
viously (Sasaki et al., 1979). Glucocorticoid
receptor assay w-as carried out on blood
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samples with > 80% blasts. The assay of the
enzyme activity used leukaemic blasts separ-
ated from marrow aspirates.
Morphological and cytochemical studies.-
The smears from peripheral blood or marrow
in each case were stained as follows and used
for differential diagnosis of leukaemias.
Wright-Giemsa, periodic acid-Schiff (PAS),
acid phosphatase, alkaline phosphatase., per-
oxidase. esterase with naphthol ASD-chloro-
acetate as substrate (NASDA), NASDA with
sodium fluoride, and nonspecific esterase
writh x-naphthyl butylate as substrate.
The effect of therapy.- Six courses of vin-
cristine (0.03 mg/kg/week) and prednisolone
(1.4 mg/kg/day) were given to the leukaemic
patients. The frequency of leukaemic blasts
( <500 ofnucleated cells) in the marrowN smear
was used as the criterion for diagnosing the
leukaemic patients as in "complete re-
mission". Patients who failed to enter into
complete remission after the therapy wiere
classified as "effective or ineffective".
Patients whose percentage of blasts in the
marrow was reduced to less than one third of
the level on admission were defined as
"effective cases". Other patients were "'in-
effective cases".
Assay for specific glucocorticoid-binding
sites. Viable cells from the peripheral blood
of patients with leukaemia were used at con-
centrations between 4 and 6 x 106 cells/ml for
the receptor assay. The receptor assay was
carried out by slightly modifying the pro-
cedure reported by Lippman et al. (1977).
Dexamethasone dissolved in ethanol was
further diluted in RPMI-1640 medium (10%
foetal calf serum). The final concentration of
ethanol to dissolve dexamethasone (<040%)
did not affect cell viability. Each cell suspen-
sion (0-8 ml) in RPMI-1640 medium (10%
foetal calf serum) was distributed into small
glass tubes. To half of these tubes, 0 2 ml of
a 5-fold concentration of 3H-dexamethasone
was added. To the other half, 0-2 ml of a
5-fold concentration of 3H-dexamethasone
plus a 100-fold excess of unlabelled dexa-
methasone wa,s added. The binding curves
were made by using varying concentrations
of 3H-dexamethasone with or without un-
labelled dexamethasone. Incubations wAere
performed for 2 h at 2100. Every 15 min, the
cells were gently mixed. After incubation, the
cell suspensions were washed x 3 with cold
PBS, and the cells were solubilized in 0 5 ml
of Soluene 350 (Packard). Each solubilized
sample was transferred to liquid-scintillation
vials, and counted in 10 ml of Dimnilume-30
(Packard). The viability of the incubated
cells was >96%, as examined by using
trypan-blue dye exclusion. Binding sites per
cell and equilibriutn dissociation constants
were calculated from Scatchard analysis
(Scatchard, 1949) assuming that each receptor
has only one steroid-binding site. Maximum
specific binding at infinite steroid concentra-
tions was obtained from the "x" intercept of
the Scatchard plot. The amount of binding,
when converted to the number of molecules
bound, divided by the cell number used for
the assay, yields the number of specific
glucocorticoid binding sites/cell.
Preparation of cell extract and enzyme
assay.-This was done as described pre-
viously (Sasaki et al., 1979). Leukaemic cells
separated from the marrowi- aspirates of fresh
leukaemia cases A-ere suspended at 108 cells/
ml in extraction buffer (50mM Tris-HCl, pH
7.6), disrupted by freezing and thawTing with
the addition of 0 250/ Triton X-100, and
centrifuged at 100,000 g for 1 h. The reaction
mixture contained 50mM Tris-HCl at pH 7.5,
30mM KCI, 0 5mM MnCk2, 2mMi dithiothreitol,
10 pg of bovine serum albumin, 0 5 u of
poly-dA, 0-25mM [3H]-dGTP and the cell
extract. Incubations were for 20 min at 37°C.
Aliquots wNere placed on Whatman GF/C
filters, and processed according to the method
of Chang & Bollum (1971). The samples were
counted in a toluene scintillator using a
liquid-scintillation spectrometer. Endogenous
radioactivity (no primer) w-as subtracted from
the activity of the poly-dA-primed reaction.
The enzyme activity was expressed as U/108
nucleated cells. One unit represents 1 nmol of
[3H]-dGMP polymerized on to poly-dA for
20 min at 37°C.
Immn nofiuorescence.- The percentage of
TdT+ cells was surveyed by using the indirect
immunofluorescence method. as reported
previously (Sasaki et al., 1980). Slides were
fixed with methanol at 4°C, incubated with
rabbit antisera against calf-thymus TdT, and
stained with fluoresceinated goat anti-rabbit
IgG (Fah')2 fiagments. Cells with fluorescent
nuclei wN-ere scored as positive. This antibody
shows good reaction with human terminal
transferase (Bollum, 1975, 1979).
Statistics. X2 test, unpaired t test or
evaluation of correlation coefficient. were
carried out for statistical analysis of the
results (Snedecor & Cochran, 1967).TERMINAL TRANSFERASE AND GLUCOCORTICOID RECEPTORS
RESULTS
Table I summarizes the effect of VP
therapy on TdT+ or TdT- leukaemias.
Twenty-two (66 7%) of 33 patients with
TdT+ leukaemia entered into complete
remission after VP therapy. Seven (21*2%)
of them showed a favourable response to
VP therapy ("effective" cases) though
they did not enter into complete remission.
Four patients (12-10o) with TdT+ leu-
TABLE I.-The effect of vincristine-predni-
solone therapy on leukaemia cases
Response to VP
thierapy
No. of - -
TdT cases CR Eff. Ineff.
ALL + 19 14 3 2
- 1 0 0 1
C(ML in BC + 14 8 4 2
11 1 4 6
VP therapy was tried as the first choice for each
patient witlh ALL or CML in blast crisis, and the
response was estimated for each case as CR (com-
plete remission) Eff. (effective) and Ineff. (ineffective)
(see MIaterials & Methods for dlefinitions). The
presence of TdT was cletermined by immuno-
fluorescent analysis.
kaemia showed a poor response to this
therapy ("ineffective" cases). However,
only 1 (8.33%) of 12 patients with TdT-
leukaemia entered into complete remis-
sion, and 4 more (33.30o) showed a favour-
able response ("effective" cases).
In Table I, the x2 test showed a sig-
nificant difference (P <0.01) between
TdT+ and TdT- leukaemias in the effect
of VP therapy.
Table II shows TdT activity, immuno-
fluorescence analysis, the frequency of
GC receptor sites and the effect of VP
therapy in patients with ALL or CML in
blast crisis. In this Table, the t test also
showed a significant difference (P<0.02)
between VP effective and ineffective cases
in level of TdT activity. As shown in
Table II, 5/6 TdT+ leukaemias showed a
moderate to high level of GC receptors
whereas, in ALL or CML in blast crisis
with no TdT activity, the level of GC
receptors was low; in other words, ALL
Cases 1-3 and Case 6 (non-T, non-B ALL)
and CML Case 3 (Phl-positive CML in
lymphoblastic crisis, null-cell type) showed
high levels of TdT and GC receptors, and
responded well to VP. In ALL Case 6,
VP induced disappearance of blasts from
peripheral blood and decreased hepato-
splenomegaly. However, blasts (27.6%
of nucleated cells) still remained in this
patient's marrow after this therapy.
Similarly, in CML Case 3, blasts (32*8% of
nucleated cells) still remained in the
marrow, although marked cytoreduction,
complete elimination of the blasts from
peripheral blood and disappearance of
splenomegalywereinducedbythistherapy.
Blasts in ALL Case 4, CML Case 1, 2
(CML in myeloblastic crisis) and 4 con-
tained low levels of GC receptor and no
TdT activity. These cases showed poor
TABLE II. TdT activities, immunoftuorescent analysis, GC receptor sites and the response
to VP therapy in leukaemias
GC receptor
Sites/cell
52242
17450
22036
5371
8652
26284
2130
8146
42363
8504
-A Response to
Kd(M x 10-9) VP therapy
8-81 CR
4-33 CR
12-82 CR
6-89 ineff.
12-20 ineff.
4-02 eff.
11-76 ineff.
8-19 ineff.
3 95 eff.
7-77 ineff.
In the bioclhemical assay, TdT- samples contained < 0-06 U/108 cells. Marrow slides from TdT- leukaemias
containe(d <1 0% positive cells on immunofluorescence analysis.
Kd(M) = (lissociation constant (molarity).
% TdT+,-
Case
ALL 1
2
3
4
5
6
CML in BC 1
2
3
4
Age
(yrs)
17
4
53
57
28
24
46
56
49
45
TdT
U/108
0-431
0-316
0-199
0-016
0-201
0-603
0-004
0-049
0-693
0-055
cells
69-6
68-2
50-5
0-4
32-3
52-1
0-4
0-8
63-1
0-7
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response to VP therapy. ALL Case 5 was
also diagnosed as non-T, non-B ALL.
However, blasts from this case contained a
low level of GC receptor, and showed poor
response to VP.
The figure shows the correlation between
TdT activity and level of GC receptor
sites of the leukaemias shown in Table II.
In these cases significant correlation
u
0.5
TdT activity (units/108 cells)
FIGURE. The correlation between the level
of TdT activity and the number of gluco-
corticoid receptor sites in ALL or CML in
blast crisis. 0, ALL responding to VP;
O, ALL, VP-ineffectiv'e; *, CML respond-
ing to VP; Oi, CMIL, VP-ineffective.
(r = 0 821, P < 0X01) was observed between
the enzyme activity and the receptor
level. Also, in Table II, there was a sig-
nificant difference (P < 001) between VP
effective and ineffective leukaemias in the
number of CC receptor sites by unpaired
t test.
DISCUSSION
It is well known that in normal tissues
of adult animals a major population of
TdT+ cells is localized in thymic cortex,
and a minor population is in certain
lymphoid cells of the marrow (Bollum,
1979). At the infantile stage of rats and
mice, another TdT+ cell population ap-
pears in peripheral blood, liver, spleen and
lung (Bollum, 1979; Sasaki et al., 1980).
Treatment of rats with dexamethasone
rapidly induces complete elimination of
TdT+ cells from all these tissues (Gregoire
et al., 1979; Sasaki et al., 1980). Therefore,
TdT+ cells in normal tissues are markedly
sensitive to glucocorticoid hormone. The
unique tissue distribution (Bollum, 1979),
glucocorticoid sensitivity and cytochemi-
cal characteristics of TdT+ cells (Sasaki
& Bollum, in preparation) strongly sup-
ports the idea that they are immature
precursors of lymphoid cells.
In leukaemia, glucocorticoid hormone
has been known as a very effective drug
for the therapy ofALL patients, > 90°0 of
whom show raised levels of TdT. Further-
more, VP therapy has recently been
suggested as effective on the treatment
of TdT+ leukaemias (Gordon et al., 1978;
Marks et al., 1978; Pangalis & Beutler,
1979; Sasaki et al., 1979).
The finding shown in Table I also sup-
ports these previous reports. Therefore,
blasts from TdT+ leukaemias may retain
glucocorticoid sensitivity likenormalTdT+
cells, even after their leukaemic transfor-
mation. However, the mechanism of the
action ofglucocorticoid hormone on TdT+
leukaemic cells still remains to be eluci-
dated.
In the leukaemia cases shown in Table
II, there was a significant correlation
between the level of TdT activity and the
number of GC receptor sites. Although
we can not draw a definite conclusion
from this preliminary result, the presence
of high or moderate levels of GC receptor
sites in blasts ofTdT+ leukaemias suggests
that (C receptor may be responsible for
the effect of VP therapy on TdT+ leu-
kaemias.
However, there are also some TdT+
leukaemias which fail to respond to VP.
TdT+ ALL (Case 5) was markedly resistant
to VP, and blasts in this case contained a
low level of GC receptors. In this case, the
heterogeneity of blasts might be respon-
sible for the low level of GC receptors and
poor response to VP. Alternatively, the
level of (C receptor sites in blasts might
be more important than the level of TdT
activity in predicting the response of
leukaemic cases to VP therapy. Further
analysis of more leukaemias into the rela-
tion between TdT activity, GC receptorsTERMINAL TRANSFERASE AND GLUCOCORTICOID RECEPTORS 67
and the effect of VP therapy is now in
progress.
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